Bacterial Pneumonia Market Report 2026

Bacterial Pneumonia Market Overview

• Bacterial Pneumonia market size has reached to $2.51 billion in 2025 • Expected to grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Impact Of Respiratory Diseases On Pneumonia Incidence • Market Trend: Advancements In Pneumococcal Vaccine Technology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bacterial Pneumonia Market?

Bacterial pneumonia is a serious and life-threatening respiratory condition caused by bacterial infections, resulting in the inflammation and accumulation of fluid or pus in the alveoli of the lungs, which impairs normal oxygen exchange and leads to symptoms such as severe cough, difficulty breathing, fever, chills, and chest pain, requiring timely medical intervention and appropriate treatment. The main types of bacterial pneumonia include community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Community-acquired pneumonia (CAP) is a lung infection contracted outside of healthcare settings, typically caused by bacteria, viruses, or fungi, leading to inflammation and impaired gas exchange in the lungs. Treatments are administered through oral, subcutaneous, or other methods and include vaccines and drugs. Distribution channels consist of hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Bacterial Pneumonia Market Growth Forecast?

The bacterial pneumonia market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increasing development of targeted antibacterial drugs, rising adoption of precision diagnostics, growing investment in vaccine development, expansion of outpatient treatment models, increasing focus on antimicrobial stewardship programs. Major trends in the forecast period include increasing adoption of advanced antibiotic therapies, rising use of rapid diagnostic testing, growing focus on antimicrobial resistance management, expansion of hospital-based treatment protocols, enhanced emphasis on preventive vaccination strategies.

Global Bacterial Pneumonia Market Segmentation

1) Ву Туре: Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP) 2) By Treatments: Vaccines, Drugs 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Community-Acquired Pneumonia (CAP): Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila 2) By Hospital-Acquired Pneumonia (HAP): Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Enterobacter spp

What Is The Driver Of The Bacterial Pneumonia Market?

The rise in prevalence of respiratory diseases is expected to drive the growth of the bacterial pneumonia market going forward. Respiratory disease refers to medical conditions that interfere with breathing and gas exchange by affecting the organs and tissues of the lungs and airway systems. The increased prevalence of respiratory diseases can be attributed to several factors, including environmental, lifestyle, demographic, and genetic contributors. Respiratory diseases increase susceptibility to bacterial pneumonia by weakening the immune system and damaging lung tissues, creating an environment for bacterial infections. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Therefore, the rise in prevalence of respiratory diseases is driving the growth of the bacterial pneumonia industry.

Key Players In The Global Bacterial Pneumonia Market

Major companies operating in the bacterial pneumonia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, GSK plc, bioMerieux SA, Shionogi & Co. Ltd., Wockhardt Limited., Zai Lab Limited, Innoviva Inc., Eagle Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc., Clarametyx Biosciences Inc., Evopoint Biosciences Inc., Vaxcyte Inc., Acurx Pharmaceuticals Inc.

Global Bacterial Pneumonia Market Trends and Insights

Major companies operating in the bacterial pneumonia market are focusing on innovations in vaccine technology, such as developing conjugate vaccines, to enhance immune response, improve efficacy, and provide broader protection against multiple bacterial strains. Conjugate vaccines link a weak antigen to a carrier protein to boost immunity effectively. For instance, in June 2024, Merck & Co. Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine). This vaccine is aimed at preventing invasive pneumococcal disease and pneumonia caused by multiple serotypes of streptococcus pneumoniae, specifically targeting adult populations aged 18 and older. This launch is significant in addressing bacterial pneumonia and other pneumococcal-related infections.

What Are Latest Mergers And Acquisitions In The Bacterial Pneumonia Market?

In June 2023, Shionogi & Co., Ltd., a Japan-based pharmaceutical company known for its infectious disease R&D capabilities, acquired Qpex Biopharma, Inc., for $140 million. With this acquisition, Shionogi aimed to bolster its antimicrobial pipeline, particularly by gaining access to Qpex’s novel β-lactamase inhibitor, xeroborbactam, to address drug-resistant Gram-negative bacterial infections. Qpex is a US-based, clinical-stage biopharma focused on developing investigational antimicrobials, including both intravenous and oral β-lactamase inhibitor-antibiotic combinations for multidrug-resistant bacterial infections.

Regional Outlook

North America was the largest region in the bacterial pneumonia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Bacterial Pneumonia Market?

The bacterial pneumonia market includes revenues earned by entities by providing services such as chest X-rays and computed tomography (CT) scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial pneumonia market consists of sales of broad-spectrum antibiotics, narrow-spectrum antibiotics, pneumococcal vaccines, mechanical ventilators, cough suppressants, and expectorants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bacterial Pneumonia Market Report 2026?

The bacterial pneumonia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial pneumonia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.